"Advances in Renal Cancer" Journalists' Award 2011 announced

Leverkusen, May 2010 – Renal cell carcinoma is one of the most common cancers worldwide. However, there still is a lack of awareness of the disease. Bayer HealthCare and the Kidney Cancer Association (KCA) have therefore announced the European “Advances in Renal Cancer” Journalists’ Award 2011. For the third time, the prize honors journalistic work, in which journalists cover the issue of renal cancer in a critical, but yet objective manner. It is endowed with the sum of Euro 7,500 and awarded to reports which have been published in print media, radio, television, or film. "Malignant tumors in kidney cells are one of the most insidious types of cancer worldwide. They are often only diagnosed at a late stage and have a significant unmet medical need”, says Helmut Schäfers, Head of Corporate Communications Europe, Bayer HealthCare, Leverkusen, Germany. “By announcing this award together with specialists in this field, we want to stimulate journalists to report on the disease and publish more information about renal carcinoma and current medical developments.” Carrie Konosky, Director of Development &Public Affairs, Kidney Cancer Association, USA, explains: “Our objective is to raise awareness of the symptoms and risk factors of renal cancer and inform the public about new, diagnostic therapy options. That is why the media are an important partner for us.” Journalists may submit their applications by Mar...
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news

Related Links:

i Francesco Massari The development of new systemic agents has led us into a “golden era” of management of metastatic renal cell carcinoma (RCC). Certainly, the approval of immune-checkpoint inhibitors and the combination of these with targeted compounds has irreversibly changed clinical scenarios. A deeper knowledge of the molecular mechanisms that correlate with tumor development and progression has made this revolution possible. In this amazing era, novel challenges are awaiting us in the clinical management of metastatic RCC. Of these, the development of reliable criteria which are able to pre...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Conclusion: This translational study identified CXCL5 as a biomarker of efficacy of lysosomotropic drugs, a potential asset for personalized medicine.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
Objective: Growing evidence suggests pretreatment fibrinogen can serve as a prognostic marker in various malignancies. However, there are contradictory results about the prognostic role of fibrinogen in urological cancers. We conducted a meta-analysis to evaluate the association between pretreatment plasma fibrinogen and survival outcomes in urological cancers.Methods: After a systematic search of PubMed and Embase, we included 14 studies in our meta-analysis, and estimated hazard ratios (HRs) for overall survival (OS) and cancer-specific survival (CSS) using a fixed-effect model.Results: Our results indicate that pretreat...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
In conclusion, our results suggested that expression status of FZD1 had a diagnostic value and prognostic value in ccRCC patients, it also may serve as a potential drug target to relieve sunitinib resistance in renal cancer patients.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Conclusion: The intrinsic and extrinsic expression patterns are both detected in ccRCC. High positive rate of TC-PD-L1 correlated closely to the strong infiltration of CD8+ TILs. TC-PD-L1-positive ccRCC patients with abundant CD8+ TILs infiltration confer the high risk of death and disease relapse.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
This study thus proposes the everolimus-ABT-737 combination as a novel therapeutic strategy for the treatment of RCC to overcome the current clinical problem of everolimus resistance.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Urothelial cell carcinoma (UCC) is the most common primary malignancy of the urinary system and the second-most common type of renal cell carcinoma. Aurora kinase A (AURKA), a serine/threonine kinase, has a critical role in centrosome duplication, spindle assembly checkpoint, and cytokinesis. Here, we determined the correlation between UCC susceptibility and AURKA polymorphisms. We used real-time polymerase chain reaction to compare the genotype distributions and allelic frequencies of four single-nucleotide polymorphisms (SNPs) of AURKA, namely rs1047972, rs2273535, rs2064863, and rs6024836, between 431 UCC cases and 862 ...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Conclusion: RN with LND cannot improve the PFS, CSS, or OS for pT3 renal cell carcinoma patients.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
In conclusion, PPARα expression was decreased in ccRCC tumors. Lower expression of PPARα is closely correlated with poorer survival. It can be used as a clinically diagnosis and prognostic biomarker in ccRCC.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Conclusions: TPM1 functions as a tumor suppressor with respect to cell proliferation, angiogenesis and metastasis in RCC, suggesting that it is a potential therapeutic target for advanced RCC.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Health | Health Management | Kidney Cancer | Nutrition | Pharmaceuticals | Renal Cell Carcinoma | Urology & Nephrology | Websites | Women